|Title: ||Steep dose-response relationship for stage I non-small cell lung cancer using hypo-fractionated high-dose irradiation by real-time tumor-tracking radiotherapy (RTRT)|
|Authors: ||Onimaru, Rikiya Browse this author →KAKEN DB|
|Fujino, Masaharu Browse this author|
|Yamazaki, Koichi Browse this author|
|Onodera, Yuya Browse this author|
|Taguchi, Hiroshi Browse this author|
|Katoh, Norio Browse this author →KAKEN DB|
|Hommura, Fumihiro Browse this author|
|Oizumi, Satoshi Browse this author →KAKEN DB|
|Nishimura, Masaharu Browse this author →KAKEN DB|
|Shirato, Hiroki Browse this author →KAKEN DB|
|Keywords: ||real-time tumor-tracking radiotherapy|
|Issue Date: ||1-Feb-2008|
|Journal Title: ||International Journal of Radiation Oncology*Biology*Physics|
|Start Page: ||374|
|End Page: ||381|
|Publisher DOI: ||10.1016/j.ijrobp.2007.06.043|
|Abstract: ||Purpose: To investigate the clinical outcomes of patients with pathologically proven, peripherally located, stage I non-small cell lung cancer (NSCLC) who received stereotactic body radiotherapy (SBRT) using real-time tumor tracking radiotherapy (RTRT) during the developmental period.
Materials and Methods: Forty-one patients were admitted (T1, 25; T2, 16) from February 2000 to June 2005. A 5 mm lanning target volume (PTV) margin was added to the clinical target volume determined with computed tomography at the end of expiratory phase. The gating window ranged from ± 2 to 3 mm. The dose fractionation schedule was 40 or 48 Gy in 4 fractions within 7 days. The dose was prescribed at the center of the PTV, giving more than an 80% dose at the PTV periphery.
Results: For 28 patients treated with 48 Gy in 4 fractions, the overall actuarial survival (OAS) at 3 years was 82% for stage IA and 32% for stage IB. For patients treated with 40Gy/4Fr/1wk, OAS at 3 years was 50% for stage IA and 0% for stage IB. There was a significant difference in local control between 40 and 48 Gy in stage IB (p=0.0015) but not in stage IA (p=0.5811). No serious radiation morbidity was observed in either dose schedule.
Conclusion: Forty-eight Gy in 4 fractions in one week was found to be a safe and effective treatment for peripherally located, stage IA NSCLC. A steep dose-response curve between 40 and 48 Gy using a daily dose of 12 Gy delivered in one week was identified for stage IB NSCLC in SBRT using RTRT.|
|Type: ||article (author version)|
|Appears in Collections:||北海道大学病院 (Hokkaido University Hospital) > 雑誌発表論文等 (Peer-reviewed Journal Articles, etc)|